{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:07Z","timestamp":1790245567933,"version":"4.1.0"},"reference-count":16,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,9,29]]},"DOI":"10.1536\/ihj.20-073","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T22:04:55Z","timestamp":1599861895000},"page":"1044-1048","source":"Crossref","is-referenced-by-count":5,"title":["Ivabradine-Induced Torsade de Pointes in Patients with Heart Failure Reduced Ejection Fraction"],"prefix":"10.1536","volume":"61","author":[{"given":"Ji-Hun","family":"Jang","sequence":"first","affiliation":[{"name":"Department of Hospital Medicine, Inha University College of Medicine"},{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Woo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Jong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"},{"name":"Division of Critical Care Medicine, Inha University College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Yong","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwang-Seok","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Huan","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Soo","family":"Beak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Don","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hee","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Ill","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Hyeok","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Inha University Hospital Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the treatment of cardiovascular diseases. Circ J 2019; 83: 252-60.","DOI":"10.1253\/circj.CJ-18-1184"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of Ivabradine. J Am Coll Cardiol 2017; 70: 1777-84.","DOI":"10.1016\/j.jacc.2017.08.038"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ponikowski P, Voors AA, Anker SD, <i>et al<\/i>. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Knuuti J, Wijns W, Saraste A, <i>et al<\/i>. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41: 407-77.","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Pei H, Miao W, Xie WZ, <i>et al<\/i>. Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure. Int Heart J 2019; 60: 899-909.","DOI":"10.1536\/ihj.18-559"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cocco G, Jerie P. Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction. Cardiovasc Toxicol 2015; 15: 104-6.","DOI":"10.1007\/s12012-014-9274-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fox K, Ford I, Steg PG, <i>et al<\/i>. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371: 1091-9.","DOI":"10.1056\/NEJMoa1406430"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16.","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Swedberg K, Komajda M, Bohm M, <i>et al<\/i>. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hidalgo FJ, Anguita M, Castillo JC, <i>et al<\/i>. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study. Int J Cardiol 2016; 217: 7-11.","DOI":"10.1016\/j.ijcard.2016.04.136"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sargento L, Satendra M, Longo S, Lousada N, dos Reis RP. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure. Am J Cardiovasc Drugs 2014; 14: 229-35.","DOI":"10.1007\/s40256-013-0060-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Fu M, Ahrenmark U, Berglund S, <i>et al<\/i>. Adherence to optimal heart rate control in heart failure with reduced ejection fraction: insight from a survey of heart rate in heart failure in Sweden (HR-HF study). Clin Res Cardiol 2017; 106: 960-73.","DOI":"10.1007\/s00392-017-1146-6"},{"key":"13","unstructured":"13. Bhatt AS, DeVore AD, DeWald TA, Swedberg K, Mentz RJ. Achieving a maximally tolerated \u03b2-blocker dose in heart failure patients: is there room for improvement? J Am Coll Cardiol 2017; 69: 2542-50."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 2014; 100: 1506-10.","DOI":"10.1136\/heartjnl-2014-305482"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67: 1639-50.","DOI":"10.1016\/j.jacc.2015.12.063"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lees-Miller JP, Guo J, Wang Y, Perissinotti LL, Noskov SY, Duff HJ. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. J Mol Cell Cardiol 2015; 85: 71-8.","DOI":"10.1016\/j.yjmcc.2015.05.009"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/5\/61_20-073\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T03:56:25Z","timestamp":1601697385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/5\/61_20-073\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-073","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}